"With means to raise antitumor immunity before tumor resection, such as chemotherapy plus IL-12, more postsurgery recurrent disease can be prevented and better outcome and survival may be possible."

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-12 Augments Antitumor Responses to Cycled Chemotherapy

  2015cited by this paper
• Preexisting antitumor immunity augments the antitumor effects of chemotherapy

  2013cited by this paper
• IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival

  2008cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• The fate of effector CD8 T cells in vivo is controlled by the duration of antigen stimulation

  2006cited by this paper
• Cutting Edge: IL-12 Induces CD4+CD25− T Cell Activation in the Presence of T Regulatory Cells1

  2005cited by this paper
• Cutting Edge: Bcl-3 Up-Regulation by Signal 3 Cytokine (IL-12) Prolongs Survival of Antigen-Activated CD8 T Cells1

  2005cited by this paper
• Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-121

  2001cited by this paper
• Localization dose and time of antigens determine immune reactivity.

  2000cited by this paper
• Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma1

  2000cited by this paper
• Immune surveillance against a solid tumor fails because of immunological ignorance.

  1999cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.

  1998cited by this paper
• Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity.

  1990cited by this paper
• Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system

  1976cited by this paper
• Contribution of host immunity to cyclophosphamide therapy of a chemically‐induced murine sarcoma

  1973cited by this paper
• Dependence of the regression of sarcoma 180 in vitamin B 6-deficient mice upon the immunologic competence of the host.

  1967cited by this paper

• No citing papers are available for this paper.